急性ST段抬高型心肌梗死患者在经皮冠状动脉介入治疗基础上辅助应用替罗非班对主要心血管不良事件发生率的影响  

Effect of adjuvant tirofiban on the incidence of major cardiovascular adverse events in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention

作　　者：肖新春 XIAO Xin-chun(Department of Cardiovascular Medicine,People's Hospital of Xingguo County,Ganzhou 342400,China)

机构地区：[1]江西省兴国县人民医院心血管内科,342400

出　　处：《中国实用医药》2023年第21期95-97,共3页China Practical Medicine

摘　　要：目的探究急性ST段抬高型心肌梗死患者在经皮冠状动脉介入治疗基础上辅助应用替罗非班对主要心血管不良事件(MACE)发生率的影响。方法60例急性ST段抬高型心肌梗死患者,随机分为对照组及观察组,每组30例。对照组应用经皮冠状动脉介入治疗,观察组在经皮冠状动脉介入治疗基础上辅助应用替罗非班治疗。比较两组患者的临床指标(TIMI 3级血流、ST段回落>50%的占比),住院期间及治疗后1年的MACE发生情况,出血事件和血小板减少症发生情况。结果观察组患者的TIMI 3级血流占比70.00%、ST段回落>50%占比73.33%大于对照组的43.33%、46.67%,差异具有统计学意义(P<0.05)。观察组患者住院期间、治疗后1年的MACE发生率分别为3.33%、6.67%,均低于对照组的20.00%、26.67%,差异具有统计学意义(P<0.05)。两组患者的出血事件、血小板减少症发生率比较,差异无统计学意义(P>0.05)。结论在急性ST段抬高型心肌梗死患者行经皮冠状动脉介入治疗时,辅助应用替罗非班具有较高的安全性,可有效降低MACE的发生率,是行经皮冠状动脉介入治疗时辅助用药的关键。Objective To investigate the effect of adjuvant tirofiban on the incidence of major cardiovascular adverse events(MACE)in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.Methods A total of 60 patients with acute ST-segment elevation myocardial infarction were randomly divided into control group and observation group,with 30 cases in each group.The control group was treated with percutaneous coronary intervention,and the observation group was treated with tirofiban in addition to percutaneous coronary intervention.Both groups were compared in terms of clinical indicators(percentage of TIMI grade 3 blood flow,percentage of ST segment resolution>50%),the occurrence of MACE during hospitalization and 1 year after treatment,bleeding events and thrombocytopenia.Results The percentage of TIMI grade 3 blood flow in the observation group was 70.00%,and the percentage of ST segment resolution>50%was 73.33%,which were higher than those of 43.33%and 46.67%in the control group,and the differences were statistically significant(P<0.05).The incidence rates of MACE in the observation group were 3.33%and 6.67%during hospitalization and 1 year after treatment,which were lower than those of 20.00%and 26.67%in the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of bleeding events and thrombocytopenia between the two groups(P>0.05).Conclusion In patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention,the application of tirofiban has high safety and can effectively reduce the incidence of MACE.It is the key to adjuvant medication during percutaneous coronary intervention.

关 键 词：急性ST段抬高型心肌梗死 经皮冠状动脉介入治疗 替罗非班 主要心血管不良事件 

分 类 号：R542.22[医药卫生—心血管疾病]